Elevated Creatine Phosphokinase in a Patient on a Long-Acting Antipsychotic: A Challenging Presentation Similar to Neuroleptic Malignant Syndrome

Prim Care Companion CNS Disord. 2023 Sep 21;25(5):22cr03442. doi: 10.4088/PCC.22cr03442.

Authors

Sahar Ashraf^{1

2}, Hansini Kochhar³, Charles Jenson⁴, Brittany Griffin⁴, Kaushal Shah⁵, Zeeshan Mansuri⁶, Anil Bachu⁴

Affiliations

¹ Northpointe Psychiatry, Lewisville, Texas.
² Corresponding Author: Sahar Ashraf, MD, Northpointe Psychiatry, 860 Hebron Pkwy, Ste 1101, Lewisville, TX 75057 ([email protected]).
³ University of La Verne, California.
⁴ Baptist Health-UAMS, North Little Rock, Arkansas.
⁵ Wake Forest University, Winston-Salem, North Carolina.
⁶ Boston Children's Hospital, Massachusetts.

PMID: 37748136
DOI: 10.4088/PCC.22cr03442

No abstract available

MeSH terms

Antipsychotic Agents* / adverse effects
Creatine Kinase
Humans
Neuroleptic Malignant Syndrome* / diagnosis
Neuroleptic Malignant Syndrome* / etiology
Patients

Substances

Antipsychotic Agents
Creatine Kinase